Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

79944-58-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

79944-58-4 Usage


Idazoxan is a benzodioxine compound that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group. It is an alpha2-adrenergic blocker, which means it can block the action of alpha2-adrenergic receptors in the body.


Used in Pharmaceutical Industry:
Idazoxan is used as an alpha2-adrenergic blocker for the treatment of various medical conditions. It works by blocking the action of alpha2-adrenergic receptors, which play a role in regulating blood pressure, heart rate, and other physiological functions. By inhibiting these receptors, Idazoxan can help to lower blood pressure and improve cardiovascular function in patients with hypertension or other related conditions.
Additionally, Idazoxan has been studied for its potential use in treating other conditions, such as glaucoma, where it may help to reduce intraocular pressure, and in the management of certain psychiatric disorders, where it may help to modulate neurotransmitter activity in the brain. However, further research is needed to fully understand the therapeutic potential of Idazoxan in these areas.

Metabolic pathway

When rats are administered radio-labeled idazoxan orally, the biotransformation of idazoxan is by hydroxylation at the 6- and 7-positions to form phenolic metabolites, which are excreted as glucuronide and sulfate metabolites in the urine, but unconjugated in the feces. Other minor metabolic pathways are 5-hydroxylation or oxidative degradation of the imidazoline ring, but these pathways are of quantitatively minor importance in rats.

Check Digit Verification of cas no

The CAS Registry Mumber 79944-58-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,9,9,4 and 4 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 79944-58:
194 % 10 = 4
So 79944-58-4 is a valid CAS Registry Number.



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017


1.1 GHS Product identifier

Product name idazoxan

1.2 Other means of identification

Product number -
Other names [125I]-Idazoxan

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:79944-58-4 SDS

79944-58-4Downstream Products

79944-58-4Relevant articles and documents



, (2009/07/02)

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

Method for treating resistant hypertension


, (2008/06/13)

A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.

Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof


Page/Page column 11, (2008/06/13)

Pharmaceutical composition comprising 5 to 20% of an idazoxan salt or of idazoxan hydrate, 10 to 40% of microcrystalline cellulose, 1 to 5% of lubricant, 0.1 to 0.5% of colloidal silica and from 29.5% to 84.8% of lactose, with respect to the total mass.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 79944-58-4